Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment: A Prospective Randomized Controlled Trial
Authors not listed
St Joseph University, Beirut, Lebanon · 2019
Abstract
Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are usually older than 45 years and their main demand is to treat pre-existing facial wrinkles. However with the increasing popularity of this technique, younger patients, aged 25 to 35 years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The usual dose used for the treatment of facial rhytides in a female patient older than 45 years is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and long lasting results in young patients. The objective of this randomized open-label study is to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2019). The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment: A Prospective Randomized Controlled Trial. <em>St Joseph University, Beirut, Lebanon</em>. https://clinicaltrials.gov/study/NCT03836638
Vancouver
Anonymous. The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment: A Prospective Randomized Controlled Trial. St Joseph University, Beirut, Lebanon. 2019.
BibTeX
@misc{anon2019TheImp,
title = {The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment: A Prospective Randomized Controlled Trial},
author = {Anonymous},
journal = {St Joseph University, Beirut, Lebanon},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Respirology 2026
Open access · OA
Frailty, Chronological Age, and Clinical Outcomes in COPD : A Nationwide Cohort Study
CHU de Reims 2014
Open access · US-GOV
Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer
JAMA Neurology 2024
Preprint · CC-BY
Frailty Trajectories Preceding Dementia in the US and UK
Ruijin Hospital 2022
Open access · US-GOV
The Efficacy and Safety of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Versus Rituximab Combined With Low-dose CHOP (R-miniCHOP) in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years: A Multicenter, Prospective, Randomized, Open-label, Controlled Trial
University of Roma La Sapienza 2020
Open access · US-GOV
PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin
European journal of medical research 2026
Open access · CC-BY